# Chinese Fibromyalgia Market

> Chinese Fibromyalgia Market Research Report By Diagnosis (Laboratory Evaluation, Presence Of Central Sensitization), Treatment (Targeted (Antidepressants, Anti-Seizure Drugs), Symptomatic Treatment, End Users (Hospitals &Clinics) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.24%
- **2024:** $ 210 Million
- **2025:** $ 222 Million
- **2035:** $ 368.4 Million
- **Key Players:** Pfizer Inc (US), Eli Lilly and Company (US), AstraZeneca PLC (GB), Novartis AG (CH), Boehringer Ingelheim GmbH (DE), Teva Pharmaceutical Industries Ltd (IL), AbbVie Inc (US), Johnson & Johnson (US)

**Report ID:** MRFR/Pharma/4175-CR · **Pages:** 85 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** March 28, 2026

**URL:** https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630

---

## Market Summary

## **Chinese Fibromyalgia Market Overview**

Chinese Fibromyalgia Market Size was valued at USD 13.45 Billion in 2023. The Global Chinese Fibromyalgia industry is projected to grow from USD 13.93 Billion in 2024 to USD 21.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.32% during the forecast period (2024 - 2032).

Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population.

For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used.  Other diagnostic procedures, such as laboratory evaluations are also used.

Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.

Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.

However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as [rheumatic diseases](../../../reports/rheumatic-fever-market-6310), neurological disorders, mental health problems, and others

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with an extensive product portfolio and pipeline, announced positive results from its clinical pharmacokinetic (PK) bridging study of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in healthy adult male and female ethnic Japanese and Chinese volunteers in February 2024.

A Sheffield woman who claimed to have perfect health after curing herself of chronic fatigue will appear on Dragons’ Den in January 2024. Giselle Boxer was working at one of the top advertising agencies when she was twenty-six years old; that is when M.E (myalgic encephalomyelitis) was diagnosed.

There has been massive research coverage and news about various aspects of fibromyalgia in China since July 2024. According to a recent cross-sectional study examining demography characteristics as well as clinical features among Chinese fibromyalgia patients, these studies concluded that fibromyalgia significantly affects the quality of life and is often accompanied by other health problems such as depression and chronic fatigue.

**Intended Audience**

**Figure: Chinese Fibromyalgia Market by Diagnosis market share, 2016 (%)**

Sources: Annual reports, Press release, White paper, Company presentation

## **Chinese Fibromyalgia Market Segmentat Insights**

The chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the chinese fibromyalgia market is classified into laboratory evaluation and presence of central sensitization**.**

On the basis of the treatment, the chinese fibromyalgia market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the chinese fibromyalgia market is segmented into hospitals, clinics, diagnostic centers, and others.

**Research Methodology**

Sources: Annual reports, Press release, White paper, and Company presentation

**Key Findings**

## **Chinese Fibromyalgia Market Regional Analysis**

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.

## **Chinese Fibromyalgia Market Key Players**

Some of key the players in the chinese fibromyalgia market are 

## Market Drivers

### Advancements in Medical Research

Ongoing advancements in medical research related to fibromyalgia are significantly influencing the China Fibromyalgia Market. Research institutions and universities in China are increasingly focusing on understanding the pathophysiology of fibromyalgia, which may lead to the development of novel treatment modalities. For instance, studies exploring the role of neuroinflammation and genetic predisposition are gaining traction. This research not only enhances the understanding of fibromyalgia but also paves the way for innovative therapies, including biologics and personalized medicine. As new treatments emerge, they are likely to capture the attention of healthcare providers and patients alike, thereby expanding the market. The synergy between research and clinical application is expected to drive growth in the China Fibromyalgia Market.

### Enhanced Patient Support Systems

The establishment of enhanced patient support systems is a crucial driver for the China Fibromyalgia Market. Support networks, including online forums, local support groups, and educational resources, are becoming increasingly available for individuals with fibromyalgia. These systems provide patients with valuable information, emotional support, and a sense of community, which can significantly improve their quality of life. Furthermore, advocacy organizations are working to raise awareness about fibromyalgia, pushing for better recognition and treatment options within the healthcare system. As these support systems grow, they are likely to encourage more individuals to seek diagnosis and treatment, thereby expanding the patient base. This trend indicates a positive trajectory for the China Fibromyalgia Market, as increased patient engagement can lead to higher demand for therapies and services.

### Rising Prevalence of Fibromyalgia

The increasing prevalence of fibromyalgia in China is a notable driver for the China Fibromyalgia Market. Recent estimates suggest that approximately 2-4% of the population may be affected by this condition, translating to millions of individuals. This growing patient base necessitates enhanced healthcare services and treatment options, thereby propelling market growth. As awareness of fibromyalgia expands, healthcare providers are more likely to recognize and diagnose the condition, leading to increased demand for therapies and support. Furthermore, the Chinese government has initiated various health policies aimed at improving chronic [pain management](https://www.marketresearchfuture.com/reports/pain-management-market-5975), which could further stimulate the China Fibromyalgia Market. The combination of rising prevalence and supportive policies indicates a robust market potential.

### Government Initiatives and Policies

Government initiatives and policies aimed at improving healthcare access and chronic pain management are pivotal for the China Fibromyalgia Market. The Chinese government has recognized the need for better management of chronic conditions, including fibromyalgia, and has implemented various health reforms. These reforms focus on enhancing healthcare infrastructure, increasing funding for pain management programs, and promoting awareness campaigns. Such initiatives are likely to improve diagnosis rates and treatment accessibility for fibromyalgia patients. Additionally, the integration of fibromyalgia management into national health strategies could lead to increased funding for research and development of new therapies. Consequently, these government actions are expected to bolster the China Fibromyalgia Market.

### Growing Demand for Alternative Therapies

The growing demand for alternative therapies in China is emerging as a significant driver for the China Fibromyalgia Market. Many patients are seeking holistic and non-pharmacological approaches to manage their fibromyalgia symptoms, including acupuncture, [herbal medicine](https://www.marketresearchfuture.com/reports/herbal-medicine-market-3250), and mindfulness practices. This trend reflects a broader shift towards integrative healthcare, where patients prefer treatments that address both physical and emotional aspects of their condition. The increasing acceptance of alternative therapies among healthcare providers further supports this demand. As more patients turn to these options, the market for alternative treatments is likely to expand, creating new opportunities within the China Fibromyalgia Market. This diversification of treatment options may enhance patient satisfaction and improve overall health outcomes.

## Future Outlook

The China Fibromyalgia Market is projected to grow at a 5.24% CAGR from 2025 to 2035, driven by increasing awareness, improved diagnostics, and innovative treatment options.

**New opportunities:**

- Development of telehealth platforms for remote patient management.
- Investment in personalized medicine targeting fibromyalgia symptoms.
- Expansion of integrative care models combining traditional and alternative therapies.

By 2035, the market is expected to be robust, reflecting significant advancements in treatment and patient care.

## Segment Insights

### By Application: Pain Management (Largest) vs. Sleep Disorders (Fastest-Growing)

In the China Fibromyalgia Market, the application segment is led primarily by Pain Management, which captures the largest share due to the high prevalence of chronic pain conditions among fibromyalgia patients. This segment is supported by a wide range of treatment options including medication and alternative therapies tailored specifically for pain relief. Following this, Sleep Disorders is emerging as the fastest-growing segment, as the understanding of sleep-related complications in fibromyalgia continues to rise. Increasing awareness regarding the correlation between pain and sleep issues is propelling innovations in this area.

Pain Management (Dominant) vs. Physical Therapy (Emerging)

The Pain Management segment stands out as the dominant force within the application segment of the China Fibromyalgia Market. It encompasses various therapeutic approaches, including pharmacological treatments and non-pharmacological methods like acupuncture and cognitive behavioral therapy, which are essential for managing the chronic pain typical of fibromyalgia. In contrast, Physical Therapy is gaining traction as an emerging application, recognized for its potential to address mobility issues and improve quality of life. This segment is increasingly being integrated into holistic treatment regimens, drawing attention as patients seek comprehensive and functional approaches to managing their symptoms. The growth in this area reflects a paradigm shift towards ensuring physical well-being alongside pain relief.

### By Treatment Type: Pharmacological (Largest) vs. Non-Pharmacological (Fastest-Growing)

In the China Fibromyalgia Market, the treatment type segment demonstrates a diverse distribution among various values. Pharmacological treatments form the largest share, catering primarily to patients seeking immediate relief from pain and discomfort associated with fibromyalgia. This segment includes a wide range of medications, ranging from analgesics to antidepressants, which are widely prescribed to manage symptoms. Non-Pharmacological treatments, meanwhile, are gaining momentum rapidly, appealing to a growing number of patients who prefer holistic and alternative approaches to fibromyalgia management. As awareness around these alternatives increases, more patients are opting for these non-invasive methods.

The growth trends for the treatment types in the China Fibromyalgia Market are influenced by several key factors. The increasing prevalence of fibromyalgia in the region has heightened the need for effective treatments, thus propelling both pharmacological and non-pharmacological segments. In addition, the rise of wellness culture and patient empowerment is steering the market towards non-pharmacological therapies, which include lifestyle modifications, physical rehabilitation, and psychological interventions. As stakeholders continue to invest in research and education around these alternative therapies, we can expect an upward trend in their adoption, further expanding the treatment options available to fibromyalgia patients in China.

Pharmacological (Dominant) vs. Non-Pharmacological (Emerging)

In the context of the China Fibromyalgia Market, Pharmacological treatments represent the dominant approach, primarily favored for their immediate and potent effects on symptom relief. This segment encompasses traditional medications such as analgesics, anticonvulsants, and antidepressants, which are well-established in clinical practice. On the other hand, Non-Pharmacological therapies are emerging as a popular alternative, driven by a growing patient preference for natural and holistic approaches. These may include therapies like cognitive behavioral therapy, yoga, and acupuncture, offering coping strategies and therapeutic benefits without the side effects associated with drugs. As the healthcare system evolves to include these diverse treatment modalities, both segments are likely to coexist, catering to the varied needs of fibromyalgia patients in China.

### By Patient Demographics: Age Group (Largest) vs. Socioeconomic Status (Fastest-Growing)

In the China Fibromyalgia Market, the largest demographic segment is determined by age group, with a significant proportion of patients falling within the 40-60 age range. This group constitutes the majority of market share, influenced by rising prevalence rates of fibromyalgia among middle-aged adults. Gender demographics indicate a higher prevalence in females compared to males, further shaping market dynamics. Additionally, socioeconomic status plays a crucial role, as individuals with higher education and income levels more frequently seek treatment and support for fibromyalgia.

Growth trends in this segment are driven by an aging population and increased awareness of fibromyalgia symptoms among healthcare professionals and patients. Emerging data also highlights a surge in fibromyalgia reports among younger adults, slighting the initial perception that this condition primarily affects older individuals. Factors such as improved diagnostic capabilities and enhanced patient education are promoting quicker diagnoses and treatment among diverse socioeconomic groups, illustrating the evolving landscape of patient demographics in this market.

Age Group (Dominant) vs. Socioeconomic Status (Emerging)

The Age Group segment remains the dominant demographic in the China Fibromyalgia Market, particularly among individuals aged 40-60, who often display a higher incidence of chronic pain conditions such as fibromyalgia. This group is characterized by various lifestyle factors including work-related stress, sedentary habits, and lack of physical activity, all of which contribute to the condition's prevalence. On the other hand, the socioeconomic status segment is emerging as a key player in shaping treatment access and outcomes. Individuals from higher socioeconomic backgrounds generally have better access to healthcare services and educational resources, facilitating quicker diagnoses and tailored treatment plans. This evolving dynamic showcases the importance of addressing various age-related and socioeconomic factors in the overall management of fibromyalgia in China.

### By Healthcare Setting: Primary Care (Largest) vs. Telehealth Services (Fastest-Growing)

In the China Fibromyalgia market, the distribution of healthcare settings reflects a diverse landscape. Primary Care dominates the sector, serving as the first point of contact for patients, while Specialty Clinics and Rehabilitation Centers play pivotal roles in offering specialized care and therapy options. Home Healthcare is emerging as a viable solution for chronic pain management, and [Telehealth Services](https://www.marketresearchfuture.com/reports/telehealth-service-market-43509) have surged in popularity due to their accessibility and convenience, especially post-pandemic. As patients seek comprehensive management solutions, these settings will likely continue to adapt and evolve to meet emerging demands.

Primary Care: Dominant vs. Telehealth Services: Emerging

Primary Care is a cornerstone of fibromyalgia management in China, providing essential services that promote early diagnosis and continuous patient care. These settings are key for managing the complexities associated with fibromyalgia, offering pain management, psychological support, and referrals to specialist services. In contrast, Telehealth Services have recently emerged as a rapid advancement in healthcare delivery, driven by the need for remote consultation and monitoring. With increased internet penetration and a growing acceptance of digital health solutions, Telehealth Services are reshaping patient engagement and access to care, offering flexibility and additional support for those with chronic conditions.

## Competitive Benchmarking

The Fibromyalgia Market in China is characterized by a complex competitive landscape, driven by increasing awareness of the condition and a growing demand for effective treatment options. Key players such as Pfizer Inc (US), Eli Lilly and Company (US), and Novartis AG (CH) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. These companies are not only investing in research and development to enhance their product offerings but are also exploring partnerships to leverage local expertise and distribution networks, thereby enhancing their competitive positioning.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to better serve the Chinese market. The competitive structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like AstraZeneca PLC (GB) and AbbVie Inc (US) is significant, as they implement strategies that emphasize both product differentiation and customer engagement, which are crucial in a market that demands tailored solutions.

In December 2025, Pfizer Inc (US) announced a collaboration with a leading Chinese biotechnology firm to develop a novel treatment for fibromyalgia, aiming to leverage local insights and accelerate the drug's market entry. This strategic move underscores Pfizer's commitment to innovation and its recognition of the unique needs of the Chinese patient population, potentially enhancing its market share in a competitive environment.

In November 2025, Eli Lilly and Company (US) launched a digital health platform designed to support fibromyalgia patients in managing their symptoms more effectively. This initiative not only reflects the growing trend of digitalization in healthcare but also positions Eli Lilly as a leader in patient-centric solutions, which could foster greater brand loyalty and improve treatment adherence among patients.

In October 2025, Novartis AG (CH) expanded its clinical trial program in China, focusing on a new therapeutic approach for fibromyalgia. This expansion is indicative of Novartis's strategic focus on research and development, as it seeks to establish a robust pipeline of innovative therapies tailored to the Chinese market, thereby enhancing its competitive edge.

As of January 2026, the Fibromyalgia Market is witnessing trends such as increased digitalization, sustainability initiatives, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming increasingly important, as companies recognize the value of collaboration in navigating the complexities of the healthcare landscape. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technology, and supply chain reliability, which will be essential for sustaining growth in this dynamic market.

## Report Scope

| MARKET SIZE 2024 | 210.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 222.0(USD Million) |
| MARKET SIZE 2035 | 368.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.24% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer Inc (US), Eli Lilly and Company (US), AstraZeneca PLC (GB), Novartis AG (CH), Boehringer Ingelheim GmbH (DE), Teva Pharmaceutical Industries Ltd (IL), AbbVie Inc (US), Johnson & Johnson (US) |
| Segments Covered | Application, Treatment Type, Patient Demographics, Healthcare Setting |
| Key Market Opportunities | Growing demand for innovative pain management solutions in the China Fibromyalgia Market. |
| Key Market Dynamics | Rising awareness and diagnosis of fibromyalgia drive demand for innovative treatment options in China's healthcare market. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What is the current valuation of the China Fibromyalgia Market?**
A: The market valuation was 210.0 USD Million in 2024.

**Q: What is the projected market size for the China Fibromyalgia Market by 2035?**
A: The projected valuation for 2035 is 368.4 USD Million.

**Q: What is the expected CAGR for the China Fibromyalgia Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 5.24%.

**Q: Which companies are the key players in the China Fibromyalgia Market?**
A: Key players include Pfizer Inc, Eli Lilly and Company, AstraZeneca PLC, and others.

**Q: What are the primary applications in the China Fibromyalgia Market?**
A: Key applications include Pain Management, Sleep Disorders, and Mental Health.

**Q: How does the Pain Management segment perform in terms of valuation?**
A: The Pain Management segment was valued between 80.0 and 140.0 USD Million.

**Q: What treatment types are prevalent in the China Fibromyalgia Market?**
A: Prominent treatment types include Pharmacological, Non-Pharmacological, and Complementary Therapies.

**Q: What demographic factors influence the China Fibromyalgia Market?**
A: Demographic factors include Age Group, Gender, and Lifestyle Factors.

**Q: What healthcare settings are involved in the China Fibromyalgia Market?**
A: Healthcare settings include Primary Care, Specialty Clinics, and Home Healthcare.

**Q: What is the projected growth trend for the Lifestyle Management segment?**
A: The Lifestyle Management segment is expected to grow from 35.0 to 63.4 USD Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630*